Cancer Immunol Res. 2026 Mar 17. doi: 10.1158/2326-6066.CIR-24-1216. Online ahead of print. ABSTRACT In humans and mice, the T cell receptor (TCR) of each effector/memory T cell clone recognizes from one to several cognate peptide-MHC complexes (pMHC). Limited knowledge on TCR repertoire specificities restricts our capacity to rationally interpret this information, both diagnostically and in … Read more
Cancer Immunol Res. 2026 Mar 13. doi: 10.1158/2326-6066.CIR-25-0651. Online ahead of print. ABSTRACT Interleukin-1 (IL-1) plays dual functions in cancer. It promotes cancer-related inflammation and progression, but also influences leukocyte functional activation. IL-1 receptor 2 (IL-1R2) functions as an IL-1 decoy receptor, inhibiting IL-1 activity. Here, we investigated the contribution of IL-1R2 in tuning IL-1-dependent … Read more
Cancer Immunol Res. 2026 Mar 4. doi: 10.1158/2326-6066.CIR-25-0950. Online ahead of print. ABSTRACT Merkel cell carcinomas (MCC) typically arise from clonal integration of the Merkel cell polyomavirus. Immunogenic viral oncoproteins then lead to tumorigenesis. Oncoprotein-specific T cells are essential for anti-MCC immunity, but it is unclear whether B cells promote tumor control. Here, we analyzed … Read more
Cancer Immunol Res. 2026 Mar 4;14(3):373. doi: 10.1158/2326-6066.CIR-14-3-WWR. NO ABSTRACT PMID:41777151 | DOI:10.1158/2326-6066.CIR-14-3-WWR
Cancer Immunol Res. 2026 Feb 27. doi: 10.1158/2326-6066.CIR-25-0611. Online ahead of print. ABSTRACT Providing cytokine signaling is a key strategy to boost the efficacy of chimeric antigen receptor (CAR) T cell therapy. However, the individual roles of key downstream mediators, STAT3 and STAT5, remain incompletely understood. In this study, we engineered CAR T cells to … Read more
Cancer Immunol Res. 2026 Feb 27. doi: 10.1158/2326-6066.CIR-25-1229. Online ahead of print. ABSTRACT Natural killer (NK) cells represent key effectors of antitumor immunity, yet emerging evidence highlights populations with distinct roles in cancer. Despite such expanded diversity within the NK cell repertoire, we lack an understanding of how this heterogeneity impacts immune responses and downstream … Read more
Cancer Immunol Res. 2026 Feb 25. doi: 10.1158/2326-6066.CIR-25-1060. Online ahead of print. ABSTRACT Immune checkpoint inhibitors (ICI), including those that block PD-1/PD-L1, have revolutionized therapy for patients with non-small cell lung cancer. However, most patients demonstrate no clinical benefit or acquire resistance, even when tumors express PD-L1. This highlights the critical need to dissect tumor … Read more
Cancer Immunol Res. 2026 Feb 25. doi: 10.1158/2326-6066.CIR-25-0758. Online ahead of print. ABSTRACT The existence of intra-tumoral tertiary lymphoid structures (TLSs) has been reported to be correlated with reduced recurrence of hepatocellular carcinoma (HCC). However, the cellular characteristics and driving mechanism of TLSs in HCC remain largely unknown. In this study, we compared clinical outcomes … Read more
Cancer Immunol Res. 2026 Feb 25. doi: 10.1158/2326-6066.CIR-25-0836. Online ahead of print. ABSTRACT Immunotherapies have revolutionized the treatment of hepatocellular carcinoma (HCC), yet their response rates remain limited, highlighting the need for new therapeutic targets. In this study, we found that VSIG4 (V-set and immunoglobulin domain containing 4) is predominantly expressed by macrophages in both … Read more
Cancer Immunol Res. 2026 Feb 24. doi: 10.1158/2326-6066.CIR-25-1381. Online ahead of print. ABSTRACT Anti-CD19 chimeric antigen receptor (CAR) therapy demonstrated remarkable efficacy against hematological malignancies. However, B cell malignancies with lymph node (LN) involvement frequently remain resistant. Here, we show that CAR T cells downregulated the chemokine receptor CCR7, crucial for nodal homing, during manufacturing. … Read more
